Second Alzheimer’s antibody approved in the US
By 
Anthony King2023-01-12T15:40:00
Biogen–Eisai’s lecanemab can slow disease progression a little, but at significant cost and risk of side effects
A second anti-amyloid antibody treatment for Alzheimer’s disease has been approved by the US Food and Drug Administration (FDA). Biogen and Eisai’s Leqembi (lecanemab) has been granted accelerated approval, and clinical trial data show it can slow progression of the disease, but clinicians have made it clear that the drug is not a cure.